ALS INVESTMENT FUND 

We are a Venture Capital fund that invests in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus in ALS. 

 

Neurodegenerative diseases are one of the main health challenges of humankind

We all want to live longer with sound minds and strong bodies. In order to do this we must tackle the challenge of chronic diseases that destroy the neurons controlling our minds, muscles, and other areas of the body. Alzheimer’s disease, Parkinson’s disease, and ALS all result from this fundamental problem of dying neurons. 

INVESTMENT PHILOSOPHY

We invest in biotech companies with balanced teams applying cutting edge technologies. We look for companies with either platform approaches relevant to multiple diseases, and/or with multiple drugs already in clinical development. The companies in our portfolio have already proven the basic science behind their approaches and are working towards a value inflection point.

Read more about the profile of our investments here and our portfolio here.

“To date we are managing the biggest most diversified portfolio of ALS related companies worldwide.”

NICHE INVESTMENT WITH A BROAD REACH

We are a highly specialized biotech investor. We currently manage the largest and most diversified portfolio of ALS related companies worldwide. We are also globally among the most diversified VC funds in neurodegeneration in general with the ambition to build out this position. The knowledge we gather through our portfolio and our longstanding relationships with a global ALS-related network of scientists, clinicians, foundations, and patient advocates, differentiates us from other investors. Read more.

"By specialization a disease focused VC Fund offers unique added value to investors, portfolio companies and ultimately to patients"

TEAM

Our mission is to advance companies developing treatments for neurodegenerative disease and ALS in particular. Our commitment to this mission is fueled by personal ties to ALS. Never losing sight of this mission, we have joined our complementary skills and years of experience together in order to successfully bring novel drugs and technologies to the market and make a return for our investors (social impact as well as financial return). [Read more].  Our scientific advisory board is comprised of internationally renowned key opinion leaders. Read here

The ALS Investment Fund is managed by SUNU Ventures BV, a Dutch limited company.

TIMELINE

2021
2021
2020
2020
2019
2018
2018
2018
2017
2017
2017
2017
2016
2016
2016
2016
2015
2015
Q2'21
FDA clears IND for ALS study Apic Bio
Q1'21
Prilenia enrolls first ALS patient Phase II/III
Q4'20
Emulate unveils brain chip
Q3'20
Sixth Investment: Prilenia
Q4'19
Amylyx presents positive Phase II data ALS
Q4'18
5th investment: ApicBio
02'18
4th investment: Emulate
Q4'18
Follow-on investment: Amylyx
Q4'17
IPO Orphazyme
Q2'17
1st institutional investor
Q1'17
New partner joins ex managing director Bain Capital
Q1'17
2nd investment: Orphazyme
Q3'16
1st investment of ALS-IF: Amylyx Inc.
Q2'16
First commitments from limited partners
Q2'16
CSO, investment committee and scientific board appointed
Q1'16
Life Sciences Parters advises with set-up
Q3'15
Qurit foundation founded to support initiation of the VC fund
Q2'15
3 ALS patients develop the concept of a VC fund specializing in ALS

NEWS

Prilenia enrolls first ALS patient in their Phase II / III study
Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
Prilenia shows positive effect on functional capacity in Huntigton’s Disease
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
Emulate signs a strategic partnership with the FDA
Amylyx announces data in Muscle & Nerve demonstrating survival benefit
FDA starts priority review of Orphazyme’s therapy in Niemann Pick Disease
Amylyx announces New England Journal of Medicine publication demonstrating benefit of their therapy in ALS
Encouraging data about first treatment of two SOD1 ALS patients with Apic’s gene therapy published in New England Journal of Medicine
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial
Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
Search for cure against the lethal disease ALS boosted by new investor
Orphazyme closes a €14 million Series B Extension
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  
Project ALS and Amylyx Enter Collaboration to Test AMX0035  
Amylyx closes a $ 5 million Series A Investment
Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  
Verge Genomics announces $32 Million Series A to Lead Artificial Intelligence-Driven Drug Discovery
Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO

ALS Investment Fund I is managed by:

SUNU Ventures
Amsterdam, The Netherlands
E: 
contact@alsinvestmentfund.com

Visting address:

Kerkstraat 342, 1017 JA Amsterdam

Copyright ©2021 SUNU Ventures BV – All rights reserved  –

 Disclaimer